Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Apr;20(4):555-565.
doi: 10.1080/14787210.2022.2012155. Epub 2021 Dec 22.

Evaluation of favipiravir in the treatment of COVID-19 based on the real-world

Weishang Deng  1 , Changyuan Yang  1 , Sensen Yang  1 , Haitao Chen  1 , Zhikun Qiu  1 , Jisheng Chen  1
Affiliations
Meta-Analysis

Evaluation of favipiravir in the treatment of COVID-19 based on the real-world

Weishang Deng et al. Expert Rev Anti Infect Ther. 2022 Apr.

Abstract

Background: The role of favipiravir (FVP) as a COVID-19 treatment is recognized but not fully elucidated. We aimed to evaluate whether FVP has definite clinical efficacy and safety in the treatment of COVID-19.

Methods: International and Chinese databases were searched for randomized controlled clinical trials evaluating FVP for the treatment of COVID-19. A meta-analysis was performed and published literature was synthesized to evaluate the corresponding therapeutic effects.

Results: We included 13 studies (1430 patients in total). Meta-analysis showed that patients with mild-to-moderate disease treated with FVP had a significantly higher viral clearance rate than those in the control group 10 and 14 days after initiation of treatment [RR: 1.13 (95% CI: 1.00, 1.28), P = 0.04; I2 = 39% for day 10 and RR: 1.16 (95% CI: 1.04, 1.30), P = 0.008; I2 = 38% for day 14] and a significantly shorter hospital stay [MD: -1.52 (95% CI: -2.82, -0.23), P = 0.02; I2 = 0%].

Conclusions: FVP significantly promotes viral clearance and reduces the hospitalization duration in mild-to-moderate COVID-19 patients, which can reduce the risk of severe disease outcomes in patients. However, more importantly, the results showed no benefit of FVP in severe patients, and caution should be taken regarding the treatment options of FVP in severe patients.

Keywords: Antiviral agents; covid-19; favipiravir; meta-analysis; viral clearance.

Plain language summary

PLAIN LANGUAGE SUMMARYThe urgent need to identify effective interventions to treat novel coronavirus infections is a major challenge. The role of favipiravir (FVP) as a COVID-19 treatment is recognized but not fully elucidated. Our study showed a significant correlation between viral clearance and the promotion of clinical improvement with FVP in mild-to-moderate patients, which is significant for reducing the length of hospital stay of patients, reducing the risk of patients progressing to severe disease, thereby reducing mortality. However, the results showed no benefit of FVP in severe patients and the conclusion of this study still needs to be further verified by clinical trials with large samples.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of literature search and study selection
Figure 2.
Figure 2.
Forest plot for Favipiravir in COVID-19
Figure 3.
Figure 3.
Forest plot for Favipiravir in COVID-19
See this image and copyright information in PMC

References

    1. Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
    1. Vaira LA, Hopkins C, Salzano G, et al. Olfactory and gustatory function impairment in COVID-19 patients: italian objective multicenter-study. Head Neck. 2020;42(7):1560–1569. - PMC - PubMed
    1. Geremia N, Vito AD, Gunnella S, et al. A Case of Vasculitis-Like Skin Eruption Associated With COVID-19. Infectious Disease in Clinical Practice. 2020;28(6): e30–e31
    1. De Vito A, Fiore V, Princic E, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS One. 2021;16(3):e0248009. - PMC - PubMed

Publication types

LinkOut - more resources